Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine What are the side effects of Cagrisema? Common and Serious Side Effects Explained Understanding Cagrilintide: Benefits and Uses